/
Oncology
Extensive-Stage Small-Cell Lung Cancer
25
Pipeline Programs↗
21
Active Trials↗
14
Companies Involved↗
Extensive-stage Small-cell Lung Cancer is an emerging landscape with 25 programs across 14 companies. The most active players are Qilu Pharmaceutical Co., Ltd., Novartis, Sichuan Baili Pharmaceutical Co., Ltd.. 14 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Phase 11
Phase 27
Phase 314
Approved
No programs
Analysis
Modality Breakdown
75%
Small molecule
18 of 24 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 24 classified programs, each share of the total. Modality classified for 96% of 25 pipeline programs.
Analysis
Trial Status
26
clinical trials
Recruiting12 · 46%
Active, not recruiting6 · 23%
Completed4 · 15%
Not yet recruiting3 · 12%
Suspended1 · 4%
Clinical Trials
Trial Activity
26 trials
Page 1 of 2
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)